{"schema_version":"secwatch.filing_event.v1","accession":"0000929638-23-003066","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.497838+00:00","generated_at":"2026-06-08T07:55:13.615537+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"enGene finalizes employment agreements with CEO, COO, CSO, CTO; salaries $450k-$590k","bullets":["CEO Jason Hanson: $590k base, 55% annual bonus target, 12-month severance non-CIC, 18-month CIC.","COO Alex Nichols: $475k base, 40% bonus target, 12-month severance non-CIC, 12-month CIC.","CSO James Sullivan: $485k base, 40% bonus target, 12-month severance non-CIC, 12-month CIC.","CTO Anthony Cheung: $450k base, 40% bonus target, 18-month severance (non-CIC and CIC).","All agreements effective Nov 1, 2023; cover restrictive covenants, equity acceleration, and COBRA."],"urls":{"canonical":"https://secwatch.observer/filing/0000929638-23-003066","json":"https://secwatch.observer/filing/0000929638-23-003066.json","markdown":"https://secwatch.observer/filing/0000929638-23-003066.md","text":"https://secwatch.observer/filing/0000929638-23-003066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823003066/0000929638-23-003066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823003066/a8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:55:13.615537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}